In addition, the combination of anti-PD-1 and anti-CTLA-4 has been authorized as a first line therapy for individuals with unresectable or metastatic melanoma, which achieved an objective response rate of 59% [64, 65]. This evidence concerns the gene CTLA4 and metastatic melanoma.